BioNexus Gene Lab
BGLC
4 hedge funds and large institutions have $558 invested in BioNexus Gene Lab in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
0.58% less ownership
Funds ownership: 0.6% → 0.02% (-0.58%)
98% less capital inflows, than outflows
Capital inflows: $552 | Capital outflows: $27K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$319 |
| 2 |
Caitong International Asset Management
Hong Kong
|
+$211 |
| 3 |
Tower Research Capital (TRC)
New York
|
+$19 |
| 4 |
JP Morgan Chase
New York
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
-$27K |
BGLC Hedge Fund Activity: Q3 2026 in Review
4 of the 8,217 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q3 2026, worth a combined $558 — down 98% from $27.2K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BGLC positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $319. The largest seller was HRT Financial, exiting entirely with an estimated $27K sold.
- 4 institutional investors held BioNexus Gene Lab (BGLC) as of Q3 2026, up from 3 in Q2 2026.
- Funds reported $558 of BioNexus Gene Lab stock for Q3 2026, down 98% quarter-over-quarter.
- 2 funds opened new BioNexus Gene Lab positions in Q3 2026 and 1 closed out, a net change of +1 holder.
- The largest BioNexus Gene Lab buyer in Q3 2026 was UBS Group, an estimated $319 added.
- The largest BioNexus Gene Lab seller in Q3 2026 was HRT Financial, an estimated $27K sold.
Based on aggregated 13F filings for Q3 2026.